Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225
NorthStar will supply non-carrier added Actinium-225, a radionuclide, for use with Ariceum’s first-in-class radiopharmaceutical drug, satoreotide
Berlin, Germany, and Beloit, Wisconsin, 11 December 2024 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a supply agreement for the therapeutic medical radioisotope, Actinium-225 (Ac-225).
